Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Guarneri

Showing results (141-150 of 176) with videos related to

Pageof 18
Sort By:
Dermatologic Therapy|October 4, 2019
Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observationVito Di Lernia, Luca Bianchi, Cristina Guerriero, et al.
The Journal of Dermatological Treatment|April 7, 2023
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern ItalyStefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Frontiers in Immunology|January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Biomedicines|October 27, 2022
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective StudyMartina Burlando, Gabriella Fabbrocini, Claudio Marasca, et al.
Expert Opinion on Biological Therapy|May 20, 2024
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database networkAndrea Spini, Giorgia Pellegrini, Ylenia Ingrasciotta, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Dermatology and Therapy|June 5, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate PsoriasisLuigi Gargiulo, Antonio Costanzo, Piergiorgio Malagoli, et al.
Pageof 18

Showing results (141-150 of 176) with videos related to

Sort By:
Pageof 18
Dermatologic Therapy|October 4, 2019
Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observationVito Di Lernia, Luca Bianchi, Cristina Guerriero, et al.
The Journal of Dermatological Treatment|April 7, 2023
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern ItalyStefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Frontiers in Immunology|January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Biomedicines|October 27, 2022
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective StudyMartina Burlando, Gabriella Fabbrocini, Claudio Marasca, et al.
Expert Opinion on Biological Therapy|May 20, 2024
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database networkAndrea Spini, Giorgia Pellegrini, Ylenia Ingrasciotta, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Dermatology and Therapy|June 5, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate PsoriasisLuigi Gargiulo, Antonio Costanzo, Piergiorgio Malagoli, et al.
Pageof 18